PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN), an Italian Multicenter Study
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna + Ospedale Policlinico San Martino, Ospedale Santa Croce-Carle Cuneo
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
number of PSMA-avid lesions (count)
Time frame: From baseline PET/CT through study completion, an average of 2 years
metabolic tumor volume (MTV in cm 3)
Time frame: From baseline PET/CT through study completion, an average of 2 years
maximum standardized uptake value (SUVmax, dimensionless)
Time frame: From baseline PET/CT through study completion, an average of 2 years
mean standardized uptake value (SUVmean, dimensionless)
Time frame: From baseline PET/CT through study completion, an average of 2 years
Secondary Endpoints
Prediction of Treatment Response via PSMA PET
Comparative Analysis of Imaging Modalities
Assessment of Tumor Volume Dynamics
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma); * Patients undergoing PSMA PET for pre-treatment disease staging; * Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA; * Provision of signed informed consent for study participation and data handling. Exclusion Criteria: * Inability to remain supine and still for the PET/CT image acquisition; * Prostate cancer with a known significant neuroendocrine component; * Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer.
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →